NCT06919796尚未招募2 期
Systems Biology of a mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Given Via Intradermal (ID) Injection Using Tropis Needle-Free Injection System (NFIS) or Intramuscular (IM) Injection Using Needle and Syringe
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Primary Objective
研究概览
简要总结
The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using needle and syringe
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able to understand and give informed consent
- •Adults aged 18 to 50 years old.
- •Willing and able to comply with all scheduled visits, vaccination, and laboratory tests.
- •Determined by investigator to be in good health based on medical history, targeted physical exam and laboratory testing.
- •Participants with pre-existing stable chronic medical conditions defined as condition not requiring significant change in therapy or hospitalization for worsening disease within 4 weeks from enrollment, can be included at the discretion of the investigator.
- •For women of childbearing potential: willing to engage in effective methods of contraception starting at least 30 days prior to enrollment and for the duration of the study.
排除标准
- •Receipt of blood products 90 days prior to study entry and for the duration of the study.
- •Volunteers who donated blood 60 days before screening OR will donate blood on or before D
- •Receipt of any experimental agents within 30 days or 5 half-lives whichever is longer prior to vaccination and for the duration of the study.
- •Receipt of any licensed vaccine within 60 days prior to study vaccination or planned receipt of any vaccine until 60 days later as well as receipt of COVID-19 vaccine for the duration of the study.
- •Receipt of a COVID-19 vaccine or confirmed COVID-19 in the past year or positive SARS-CoV-2 antigen test on vaccination day.
- •Chronic medical problems including (but not limited to) autoimmune disease, severe gastrointestinal disease, and grade 4 hypertension.
- •Any diseases or conditions that put individuals at increased risk for severe COVID-19 illness, including: type 1 or 2 diabetes, chronic lung disease (including moderate to severe asthma, bronchiectasis, bronchopulmonary dysplasia, chronic obstructive pulmonary disease (COPD), interstitial lung disease including idiopathic pulmonary fibrosis, pulmonary embolism, or pulmonary hypertension), cystic fibrosis, dementia, Parkinson's disease, cerebrovascular disease, chronic liver disease, chronic kidney disease (any stage), heart conditions, hemoglobin blood disorders (sickle cell disease, thalassemia).
- •BMI > 40 kg/m2
- •Any potentially immune mediated disease (with the exception of well controlled hypothyroidism).
- •Alcohol or drug abuse and psychiatric conditions that in the opinion of the investigator would preclude compliance with the trial or interpretation of safety or endpoint data.
- •Impaired immune function or chronic infections including (but not limited to) HIV, hepatitis B or C; organ transplant; active cancer or any history of hematologic cancer; receipt of chemotherapy, radiation therapy (past 12 months) or any other potentially immunosuppressive therapy [i.e. received oral, intramuscular or intravenous systemic immunosuppressants, or immune modifying drugs for >14 days in total within 6 months prior to any study vaccine dose (for corticosteroids ≥ 20 mg/day of prednisone equivalent). Note: Topical medications are allowed.], congenital immunodeficiency, anatomical or functional asplenia.
- •Pregnancy or breast feeding or planned pregnancy for the duration of the study.
- •Severe reactions to prior vaccination with Covid-19 mRNA vaccine or any of its components, including anaphylaxis.
- •History of Guillain Barré syndrome or myopericarditis.
- •Volunteers with any acute illness, including any fever (> 100.4 F [> 38.0C], regardless of the route) within 3 days prior to study entry.
- •Social, occupational, or any other condition that in the opinion of the investigator might interfere with compliance with the study and vaccine evaluation.
研究组 & 干预措施
Intramuscular injection of the mRNA Covid-19 vaccine via needle and syringe
Active Comparator
Immunization with a single dose of mRNA Covid-19 vaccine administered intramuscularly using needle and syringe
干预措施: COMIRNATY® (Biological)
mRNA vaccine administration via Tropis ID NFIS
Experimental
Immunization with a single dose of mRNA Covid-19 vaccine administered intradermally using the Tropis Needle Free Injection System
干预措施: COMIRNATY® (Biological)
结局指标
主要结局
Primary Objective
时间窗: Nine months
In 40 participants response rate, and magnitude of SARS-CoV-2-specific antibody neutralization titers will be measured at Day 30 and Month 6-9 after vaccination
次要结局
- Secondary Objective(Nine months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent VaccineCovid19SARS-CoV2 InfectionNCT04952402National Institute of Allergy and Infectious Diseases (NIAID)43
终止
不适用
Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating MedicationMultiple SclerosisNCT04796584Providence Health & Services20
招募中
不适用
Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS ApproachGenetic PredispositionNCT04873128University Hospital Tuebingen110
已完成
不适用
COVID-19 Vaccine Response in Treated MS PatientsHealthyMultiple SclerosisNCT05060354Brigham and Women's Hospital159
终止
不适用
Immune Response to SARS-CoV-2 Vaccination in Systemic LupusSystemic LupusNCT04894253University Hospital, Strasbourg, France7